CHIRLOYO Trademark
CHIRLOYO is a USPTO trademark filed by ZEALAND PHARMA A/S. Status: Pending.
Trademark Facts
| Mark | CHIRLOYO |
|---|---|
| Serial Number | 79448562 |
| Status | Pending |
| Filing Date | 2026-03-18 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals), 010 (Medical Devices), 044 (Medical Services) |
| Owner | ZEALAND PHARMA A/S |
| Prosecution Events | 3 |
| Latest Event | MAFR on 2026-04-23 |
Goods & Services
Class 005: Pharmaceutical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia.; Class 010: Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia, and parts and fittings therefor.; Class 044: Medical and pharmaceutical services, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia.